Brian T. Hill, MD, PhD

Dr. Hill and Dr. Gia discuss treatment options for patients who progress on covalent and noncovalent BTK inhibitors.

Exploring molecular mechanisms of resistance to BTK inhibitors as well as emergent data concerning how this resistance might be overcome.

Dr. Hill and Dr. Gia share how varying risk profiles of different BTK inhibitors may impact patient outcomes, along with relevant real-world data.

An insightful analysis of head-to-head trials comparing BTK inhibitors (acalabrutinib vs ibrutinib and zanubrutinib vs ibrutinib) to guide treatment selection in CLL.

Subject-matter experts review treatment options for patients with relapsed/refractory CLL.

Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).

Dr Hill closes by discussing current unmet needs in the R/R FL landscape and giving practical advice to providers caring for patients with FL.

A focused discussion on available CAR T-cell therapies for patients with R/R FL, supporting efficacy data, and how these therapies have impacted the field.

Dr Hill shares how he would have handled the patient case and discusses factors that contribute to treatment selection among third-line therapies for patients with R/R FL, including axicabtagene ciloleucel and other CAR T-cell therapies.

Insights concerning typical treatment responses experienced by patients with FL, clinical factors that may be predictive of response, and the incidence of relapsed or refractory disease.

Dr Hill continues his discussion of the case, outlining the first-, second, and third-line treatment strategies employed for this particular patient.

Brian T. Hill, MD, PhD briefly reviews the diagnosis and staging of FL, typical prognoses for patients with the disease, and begins to outline a patient case of R/R FL.

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel  in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.